Article Information
History
- February 6, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Simon C. Baker1,*,
- Andrew S. Mason1,
- Raphael G. Slip1,
- Pontus Eriksson2,
- Gottfrid Sjödahl2,
- Ludwik K Trejdosiewicz1 and
- Jennifer Southgate1
- 1Jack Birch Unit of Molecular Carcinogenesis, Department of Biology and York Biomedical Research Institute, University of York, Heslington, York YO10 5DD, UK
- 2Lund University Cancer Centre, Lunds Universitet, Box 117, 221 00 Lund, Sweden
- ↵*Contact Information for Corresponding Author (Address as above) Tel: +44 1904 328706, E-mail address: simon.baker{at}york.ac.uk
Posted February 06, 2022.
The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free and basal/squamous muscle-invasive bladder cancer survival and better targeted strategies for immune checkpoint blocking
